Business
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Data presented at the 2023 SNO/ASCO CNS Cancer ConferenceBerubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Data presented at the 2023 SNO/ASCO CNS Cancer ConferenceBerubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM) with topline data from interim analysis expected before year endHOUSTON, TX / ACCESSWIRE / August 14, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a poster presentation at the 2023 SNO/ASCO CNS Cancer Conference, held August 10-12, 2023 in San Francisco, CA.The poster, titled, \"A randomized, controlled trial of Berubicin, a topoisomerase II poison that appears to cross the blood-brain barrier (BBB), after first-line therapy for glioblastoma multiforme (GBM): Preliminary Results,\" was presented by Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals. The presented poster is now available on the Company's website.\"Berubicin has demonstrated its capability to be an innovative treatment in GBM that is safe and well tolerated, which has the potential to be a novel and effective therapy for this disease. Based on the results we've seen preclinically and in the clinic thus far, including these updated results from our on-going potentially pivotal study, we remain optimistic that Berubicin may provide a much needed clinical benefit for GBM patients. We look forward to upcoming interim results that will evaluate Berubicin compared to the current standard of care (Lomustine) for second line therapy in this disease,\" commented Dr. Silberman.As of the data cutoff for the poster, 151 patients had been enrolled, 105 on Berubicin and 46 on Lomustine. Enrolled patients received 7.5 mg/m2/day of intravenous (IV) Berubicin over 2 hours for 3 consecutive days (one cycle) every 21 days.Previous results from this study were presented in November 2022 at the Society for Neuro-Oncology (SNO) 27th Annual Meeting.Summary of Updated Results from the Potentially Pivotal Study:All patients enrolled show comparable demographics for each arm, inclu...